Expert review of respiratory medicine最新文献_第6页

Long COVID: a consequence of chronic post-infectious inflammation! 长COVID：慢性感染后炎症的结果！

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-12-06 DOI: 10.1080/17476348.2024.2438104

Joseph M Blondeau

引用次数: 0

Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer. 利用液体活检诊断和治疗肺癌的最新进展。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-03 DOI: 10.1080/17476348.2024.2423824

Valerio Gristina, Gianluca Russo, Tancredi Didier Bazan Russo, Giulia Busuito, Giuliana Iannì, Pasquale Pisapia, Claudia Scimone, Lucia Palumbo, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Viviana Bazan, Antonio Russo, Giancarlo Troncone, Umberto Malapelle, Francesco Pepe

{"title":"Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer.","authors":"Valerio Gristina, Gianluca Russo, Tancredi Didier Bazan Russo, Giulia Busuito, Giuliana Iannì, Pasquale Pisapia, Claudia Scimone, Lucia Palumbo, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Viviana Bazan, Antonio Russo, Giancarlo Troncone, Umberto Malapelle, Francesco Pepe","doi":"10.1080/17476348.2024.2423824","DOIUrl":"10.1080/17476348.2024.2423824","url":null,"abstract":"Introduction: In the era of precision medicine, liquid biopsy rapidly emerges as an integrative diagnostic tool to successfully stratify solid tumor patients in accordance with molecular fingerprinting. As the matter of fact, a plethora of analytes may be isolated from liquid biosources supporting the potential application of liquid biopsy in several clinical scenarios. Despite this promising role, liquid biopsy is drastically affected by low abundance of analytes in biological matrix requiring highly sensitive technologies, trained personnel, and optimized diagnostic procedures to successfully administrate this revolutionary diagnostic tool in clinical practice.Areas covered: This review aims to investigate the recent advancements in technical approaches available to manage liquid biopsy samples, particularly focusing on their application in LC diagnosis and treatment.Expert opinion: The rapidly evolving scenario of liquid biopsy-based approaches is revolutionizing clinical administration of lung cancer patients. Of note, the integration of genomic, epigenomic, and transcriptomic markers lays the basis for 'comprehensive' molecular fingerprinting of lung cancer patients. Here, the next-generation technologies are fundamental in molecular profiling in diagnostic routine biofluids.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"991-1001"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Some challenges in implementing updated European respiratory society (ERS)/American thoracic society (ATS)-2022 interpretive strategies for routine pulmonary function tests. 实施欧洲呼吸学会 (ERS)/ 美国胸腔学会 (ATS)-2022 更新的常规肺功能测试解释策略的一些挑战。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-14 DOI: 10.1080/17476348.2024.2428217

Mariem Abdesslem, Balsam Barkous, Helmi Ben Saad

引用次数: 0

Comparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US medicare population. 在COPD患者中，奥替特罗/噻托溴铵和维兰特罗/乌莫列地铵的比较疗效：一项与美国医疗保险人群中新用户队列研究相匹配的高维倾向评分

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-12-30 DOI: 10.1080/17476348.2024.2446598

Chintal H Shah, Robert M Reed, Linda Wastila, Eberechukwu Onukwugha, Mathangi Gopalakrishnan, Zafar Zafari

{"title":"Comparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US medicare population.","authors":"Chintal H Shah, Robert M Reed, Linda Wastila, Eberechukwu Onukwugha, Mathangi Gopalakrishnan, Zafar Zafari","doi":"10.1080/17476348.2024.2446598","DOIUrl":"10.1080/17476348.2024.2446598","url":null,"abstract":"Background: Two long-acting muscarinic antagonist inhaler fixed dose combinations (olodaterol/tiotropium (OLO/TIO) and vilanterol/umeclidinium (VI/UMEC)) have once-a-day dosing for managing chronic obstructive pulmonary disease (COPD). This study aimed to compare clinical effectiveness of these inhalers in terms of ability to prevent severe COPD exacerbations in a United States Medicare population.Research design and methods: Using nationally representative Medicare data (2013-2019), we employed a new user, active comparator design among beneficiaries aged 65 years and older with COPD. The outcome of interest was time to first occurrence of a severe COPD exacerbation. To ensure comparability between the groups, we performed 1:3 (OLO/TIO:VI/UMEC) nearest neighbor matching based on their high-dimensional propensity scores.Results: The study included 2,263 OLO/TIO new initiators matched to 6,789 VI/UMEC new initiators. The incidence rate of the first severe COPD exacerbation was 40.8 per 100 person-years among new initiators (39.9 per 100 person-years for OLO/TIO, 41.1 per 100 person-years for VI/UMEC). The adjusted hazard ratio of the time to first COPD exacerbation was 0.948 (95% Confidence interval: 0.813-1.105) for individuals initiating OLO/TIO versus VI/UMEC.Conclusion: We did not find a statistically significant difference between the OLO/TIO and VI/UMEC new users in terms of time to first severe exacerbation among Medicare COPD patients aged 65 or older.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1113-1120"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on endobronchial valve therapy for severe emphysema: real world data and special indications. 严重肺气肿的支气管内瓣膜治疗最新进展：真实世界的数据和特殊适应症。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/17476348.2024.2431522

Tadashi Sakaguchi, Jorine E Hartman, Dirk-Jan Slebos

{"title":"An update on endobronchial valve therapy for severe emphysema: real world data and special indications.","authors":"Tadashi Sakaguchi, Jorine E Hartman, Dirk-Jan Slebos","doi":"10.1080/17476348.2024.2431522","DOIUrl":"10.1080/17476348.2024.2431522","url":null,"abstract":"Introduction: Bronchoscopic lung volume reduction (BLVR) using one-way endobronchial valves (EBV) is a guideline therapy for patients with severe emphysema without interlobar collateral ventilation, based on solid results from multiple randomized clinical trials (RCTs). However, whether its efficacy and safety in real-world clinical settings are comparable to those observed in RCTs has not been fully investigated. Additionally, recent reports on EBV therapy have focused on specialized populations (e.g. very low FEV1, very low DLCO) that were not represented in the RCTs.Areas covered: We have summarized the efficacy and safety of the publications on BLVR with EBVs in real-world settings and in specialized populations, and have discussed these findings in relation to the RCTs data.Expert opinion: The benefits of BLVR with EBVs have effectively translated into real-world clinical practice with a tolerable safety profile. These benefits and acceptable safety profile were also observed in specialized populations not fully represented in RCTs. We believe it is crucial to establish a nationwide registry in each country to keep track of outcome for quality and consistency, and to have a multidisciplinary COPD team discussion in each treating institution to keep on ensuring the successful clinical practice of BLVR with EBVs.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1003-1011"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute respiratory failure in adult patients with acute myeloid leukemia. 急性髓性白血病成人患者的急性呼吸衰竭。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/17476348.2024.2433554

Dara Chean, Alexis Maillard, Amira Benattia, Sofiane Fodil, Elie Azoulay

{"title":"Acute respiratory failure in adult patients with acute myeloid leukemia.","authors":"Dara Chean, Alexis Maillard, Amira Benattia, Sofiane Fodil, Elie Azoulay","doi":"10.1080/17476348.2024.2433554","DOIUrl":"10.1080/17476348.2024.2433554","url":null,"abstract":"Introduction: Patients with acute myeloid leukemia (AML) are at high risk of developing life-threatening complications. It is estimated that a quarter of adult patients diagnosed with AML will require admission to the intensive care unit (ICU) at least once during their disease. Acute respiratory failure (ARF) is the main reason for ICU admission and is associated with high mortality rates, depending on the etiology of ARF.Areas covered: In this population, the high prevalence of severe pulmonary infections highlights the importance of immunosuppression caused by the disease and its treatment. In the early stages of the disease, in addition to pneumonia, which should be systematically sought, leukemia-specific lung involvement (leukostasis, leukemic pulmonary infiltration, and acute lysis pneumopathy) is an important cause of ARF in this population, representing up to 60% of cases. This review aims to help understand the pathophysiology and management of leukemia-specific lung involvement, based on the most contemporary literature.Expert opinion: The number of AML patients requiring ICU care is expected to increase. AML patients admitted to the ICU for ARF have a high mortality rate, but survivors have encouraging long-term outcomes. Future research will focus on improving risk stratification, cytoreduction, oxygenation strategies, and diagnostic techniques for ARF.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"963-974"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the nicotine metabolite ratio a useful tool to improve the effectiveness, safety, and adherence to quitting smoking? Systematic review of the literature and meta-analysis. 尼古丁代谢物比率是提高戒烟有效性、安全性和依从性的有用工具吗？文献的系统回顾和荟萃分析。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/17476348.2024.2429675

José Ignacio de Granda-Orive, Adolfo Alonso-Arroyo, Daniel López-Padilla, Rafael Aleixandre-Benavent, Segismundo Solano-Reina, Juan Antonio Riesco-Miranda, Carlos Rábade-Castedo, Miguel Jiménez-Gómez, Fernando Revuelta-Salgado, Carlos A Jiménez-Ruiz

{"title":"Is the nicotine metabolite ratio a useful tool to improve the effectiveness, safety, and adherence to quitting smoking? Systematic review of the literature and meta-analysis.","authors":"José Ignacio de Granda-Orive, Adolfo Alonso-Arroyo, Daniel López-Padilla, Rafael Aleixandre-Benavent, Segismundo Solano-Reina, Juan Antonio Riesco-Miranda, Carlos Rábade-Castedo, Miguel Jiménez-Gómez, Fernando Revuelta-Salgado, Carlos A Jiménez-Ruiz","doi":"10.1080/17476348.2024.2429675","DOIUrl":"10.1080/17476348.2024.2429675","url":null,"abstract":"Introduction: We have carried out a systematic review of the literature (SRL) and a meta-analysis (MA) to answer: 1. Validity of the nicotine metabolite ratio (NMR) in improving the effectiveness of pharmacological treatments (PT) for smoking cessation (SC). 2. Validity of the NMR to improve the safety of the use of these PT? and 3. Validity of NMR in improving adherence to these PT?Method: We carried out an SRL (six databases) and an MA for responding to the questions.Results: PT for SC (any treatment) is more effective in smoking subjects with slow NMR compared with fast NMR. Varenicline (VR) is equally effective in fast and slow NMR (RR 1.04 [CI 95% 0.75, 1.44]). When we compared those smokers who were treated to quit smoking with VR or nicotine replacement therapy (NRT) in fast metabolizers, we found that abstinence was in favor of those who were treated with VR (RR 1.40 [CI 95% 1.02, 1.91]). Those who were treated to quit smoking with NRT presented better results in slow Metabolizers (RR 0.70 [CI 95% 0.58, 0.83]). NMR increases the safety and adherence of treatments.Conclusions: We suggest that NMR is a good biomarker in the personalization of smoking cessation.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1073-1099"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polypharmacy in older patients with asthma: hidden risks and opportunities for improvement. 老年哮喘患者的多重用药：潜在的风险和改善的机会。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-12-23 DOI: 10.1080/17476348.2024.2444331

Alessandra Tomasello, Alida Benfante, Alessia Lisotta, Dario Macaluso, Sengottuwell Viswanathan, Katherine N Cahill, Nicola Scichilone

{"title":"Polypharmacy in older patients with asthma: hidden risks and opportunities for improvement.","authors":"Alessandra Tomasello, Alida Benfante, Alessia Lisotta, Dario Macaluso, Sengottuwell Viswanathan, Katherine N Cahill, Nicola Scichilone","doi":"10.1080/17476348.2024.2444331","DOIUrl":"10.1080/17476348.2024.2444331","url":null,"abstract":"Introduction: Polypharmacy can be considered the norm in elderly patients, because older individuals experience an increasing number of concomitant respiratory and non-respiratory diseases other than asthma, carrying the risk of drug-to-drug-interactions and drug-to-comorbidities interactions. In this context, asthma in older adults, conventionally aging >65 years of age, cannot be adequately managed without considering their individual characteristics, as these challenge the traditional therapeutic algorithms/management strategies commonly applied to younger populations.Areas covered: The current article aims at addressing pitfalls and advantages of current pharmacological strategies in older individuals with asthma. Comorbidities become more common with increasing age and are also more frequent in adults with asthma than in those without it. Multiple medications are often needed to control asthma symptoms and prevent asthma exacerbations, and older patients with asthma may also take multiple medications for common comorbidities and complex health conditions, such as chronic cardiometabolic diseases. Polypharmacy is an emerging concern in the elderly population.Expert opinion: A patient-centered approach is crucial and polypharmacy in asthma requires careful management. A multidisciplinary approach will allow for a more holistic care and will ensure that all aspects of a patient's health are considered, optimizing medication management.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1047-1059"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is new in synthetic lung surfactant protein technology? 合成肺表面活性蛋白技术有何新进展？

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-17 DOI: 10.1080/17476348.2024.2429669

Frans J Walther, Joseph A Zasadzinski, Alan J Waring

引用次数: 0

Advancements and challenges in the management of pneumonia in elderly patients with COPD. 慢性阻塞性肺病老年患者肺炎管理的进展与挑战。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1080/17476348.2024.2422961

Sebastian Ocrospoma, Antonio Anzueto, Marcos I Restrepo

引用次数: 0